Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

NASDAQ:VRDN - Nasdaq - US92790C1045 - Common Stock - Currency: USD

14.68  +0.44 (+3.09%)

After market: 14.55 -0.13 (-0.89%)

Fundamental Rating

3

Taking everything into account, VRDN scores 3 out of 10 in our fundamental rating. VRDN was compared to 558 industry peers in the Biotechnology industry. The financial health of VRDN is average, but there are quite some concerns on its profitability. VRDN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRDN had negative earnings in the past year.
VRDN had a negative operating cash flow in the past year.
In the past 5 years VRDN always reported negative net income.
VRDN had a negative operating cash flow in each of the past 5 years.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

VRDN has a Return On Assets (-46.65%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -51.01%, VRDN is in the better half of the industry, outperforming 65.41% of the companies in the same industry.
Industry RankSector Rank
ROA -46.65%
ROE -51.01%
ROIC N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRDN has more shares outstanding
VRDN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VRDN has been reduced compared to a year ago.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 9.61 indicates that VRDN is not in any danger for bankruptcy at the moment.
VRDN has a Altman-Z score of 9.61. This is amongst the best in the industry. VRDN outperforms 86.56% of its industry peers.
VRDN has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
VRDN has a worse Debt to Equity ratio (0.03) than 60.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 9.61
ROIC/WACCN/A
WACC9.87%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

VRDN has a Current Ratio of 19.49. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN has a better Current ratio (19.49) than 93.01% of its industry peers.
VRDN has a Quick Ratio of 19.49. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN's Quick ratio of 19.49 is amongst the best of the industry. VRDN outperforms 93.01% of its industry peers.
Industry RankSector Rank
Current Ratio 19.49
Quick Ratio 19.49
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

VRDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.22%, which is quite good.
The Revenue has been growing slightly by 6.34% in the past year.
VRDN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -41.64% yearly.
EPS 1Y (TTM)10.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.13%
Revenue 1Y (TTM)6.34%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%0%

3.2 Future

The Earnings Per Share is expected to grow by 23.28% on average over the next years. This is a very strong growth
VRDN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 403.12% yearly.
EPS Next Y-2.02%
EPS Next 2Y0.04%
EPS Next 3Y13.15%
EPS Next 5Y23.28%
Revenue Next Year-42.17%
Revenue Next 2Y1029.85%
Revenue Next 3Y840.89%
Revenue Next 5Y403.12%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRDN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRDN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

VRDN's earnings are expected to grow with 13.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.04%
EPS Next 3Y13.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRDN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (6/6/2025, 8:00:02 PM)

After market: 14.55 -0.13 (-0.89%)

14.68

+0.44 (+3.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-06 2025-08-06/amc
Inst Owners115.67%
Inst Owner Change0.55%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.21B
Analysts85.22
Price Target41.57 (183.17%)
Short Float %12.93%
Short Ratio11.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.55%
Min EPS beat(2)5.31%
Max EPS beat(2)11.8%
EPS beat(4)2
Avg EPS beat(4)-0.51%
Min EPS beat(4)-12.54%
Max EPS beat(4)11.8%
EPS beat(8)5
Avg EPS beat(8)1.91%
EPS beat(12)6
Avg EPS beat(12)-7.46%
EPS beat(16)8
Avg EPS beat(16)-9.31%
Revenue beat(2)2
Avg Revenue beat(2)29.64%
Min Revenue beat(2)0.65%
Max Revenue beat(2)58.63%
Revenue beat(4)3
Avg Revenue beat(4)31.36%
Min Revenue beat(4)-18.06%
Max Revenue beat(4)84.21%
Revenue beat(8)3
Avg Revenue beat(8)-4.34%
Revenue beat(12)5
Avg Revenue beat(12)13.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.77%
EPS NQ rev (1m)-1.8%
EPS NQ rev (3m)5.88%
EPS NY rev (1m)0.93%
EPS NY rev (3m)6.26%
Revenue NQ rev (1m)-37.77%
Revenue NQ rev (3m)-12.72%
Revenue NY rev (1m)-6.1%
Revenue NY rev (3m)-20.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4002.49
P/FCF N/A
P/OCF N/A
P/B 2
P/tB 2
EV/EBITDA N/A
EPS(TTM)-4.04
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-3.4
FCFYN/A
OCF(TTM)-3.4
OCFYN/A
SpS0
BVpS7.34
TBVpS7.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.65%
ROE -51.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 116.6%
Cap/Sales 197.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.49
Quick Ratio 19.49
Altman-Z 9.61
F-Score3
WACC9.87%
ROIC/WACCN/A
Cap/Depr(3y)191.45%
Cap/Depr(5y)174.87%
Cap/Sales(3y)166.8%
Cap/Sales(5y)103.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.13%
EPS Next Y-2.02%
EPS Next 2Y0.04%
EPS Next 3Y13.15%
EPS Next 5Y23.28%
Revenue 1Y (TTM)6.34%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%0%
Revenue Next Year-42.17%
Revenue Next 2Y1029.85%
Revenue Next 3Y840.89%
Revenue Next 5Y403.12%
EBIT growth 1Y-41.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.93%
EBIT Next 3Y11.83%
EBIT Next 5Y43.1%
FCF growth 1Y-106.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.57%
OCF growth 3YN/A
OCF growth 5YN/A